Latest Breaking News On - Electron microscopy data bank - Page 2 : comparemela.com
Most analyses of the antibody responses induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have focused on antibodies cloned from memory B cells. This approach has led researchers to conclude that neutralizing antibodies (nAbs) primarily target the receptor-binding domain (RBD) of the virus s spike protein. Voss et al. took a different approach, using proteomic deconvolution of the serum immunoglobulin G antibody repertoire from four COVID-19 convalescent patients. They found that the nAb response was largely directed against epitopes such as the N-terminal domain (NTD), which lie outside the RBD. Several of these nAbs were shared among donors and targeted an NTD epitope that is frequently mutated by variants of concern.
Science , abg5268, this issue p. [1108][1]
The molecular composition and binding epitopes of the immunoglobulin G (IgG) antibodies that circulate in blood plasma after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infecti
California
United-states
San-francisco
University-of-california
Lamontagne-center
Ut-system-proteomics-network
National-institute-of-allergy
Department-of-defense
Infectious-diseases-research-program
Sauer-structural-biology-laboratory
Us-army
New Artificial Intelligence Tool May Speed Up Drug Discovery Using Images
New Artificial Intelligence Tool May Speed Up Drug Discovery Using Images
Japanese researchers are using artificial intelligence (AI) to gain insights from cryo-electron microscopy.
Artificial intelligence (AI) machine learning is transforming pharmaceutical drug discovery. Advances in deep learning, a subset of machine learning, is enabling researchers to identify patterns in fields where there are large amounts of complex data, such as imaging.
In a recent study published in Nature Machine Intelligence, researchers in Japan created an AI deep neural network to extract information on protein dynamics from images captured using cryo-electron microscopy (cryo-EM).
New-york
United-states
Japan
Cambridge
Cambridgeshire
United-kingdom
Switzerland
Japanese
Shigeyuki-matsumoto
Kei-terayama
Jacques-dubochet
Takayuki-kato
Among the most promising therapeutic options for individuals with coronavirus disease 2019 (COVID-19) are monoclonal antibodies (mAbs). In this study, Jones et al . identified, characterized, and tested one such mAb, LY-CoV555, in vitro and in vivo. They found that LY-CoV555 bound to the severe acute respiratory distress syndrome coronavirus-2 (SARS-CoV-2) spike protein and prevented its interaction with angiotensin-converting enzyme 2. Prophylactic treatment with LY-CoV555 protected the upper and lower respiratory tracts of nonhuman primates from becoming infected with SARS-CoV-2. Together, these data support the clinical use of LY-CoV555 for treating patients with COVID-19.
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses a public health threat for which preventive and therapeutic agents are urgently needed. Neutralizing antibodies are a key class of therapeutics that may bridge widespread vaccination campaigns and offer a treatment solution in populations less res
South-africa
China
Italy
United-states
United-kingdom
Chinese
American
K-huntington-eli-lilly
Gatan-solarus
Isoplates-perkinelmer
Eli-lilly
Oxford-cryosystems
vimarsana © 2020. All Rights Reserved.